Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025

Heron Therapeutics, Inc. (NASDAQ: HRTX ) has four approved therapeutics, bringing in net product sales of $39M in Q1'25 between them, but the company believes one of the four drugs (Zynrelef) could be a$100M+ drug annually. I rated HRTX a buy in AprilScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst ...